Molecular Genetic Characteristics of Acute Myeloid Leukemia Patients with CBFβ-MYH11 Positive.
10.19746/j.cnki.issn.1009-2137.2022.06.006
- Author:
Yu JIANG
1
,
2
;
Hong-Ying CHAO
3
;
Xu-Zhang LU
3
;
Pin WU
4
;
Xiao-Chun SUN
5
Author Information
1. School of Medicine, Jiangsu University, Zhenjiang 212000, Jiangsu Province, China
2. Department of Clinical Laboratory, Changzhou No.2 People's Hospital, the Affiliated Hospital of Nanjing Medical University, Changzhou 213000, Jiangsu Province, China.
3. Department of Hematology, Changzhou No.2 People's Hospital, the Affiliated Hospital of Nanjing Medical University, Changzhou 213000, Jiangsu Province, China.
4. Department of Hematology, Wuxi No.2 People's Hospital, Wuxi 214000, Jiangsu Province, China.
5. School of Medicine, Jiangsu University, Zhenjiang 212000, Jiangsu Province, China. E-mail: xiaochun@ujs.edu.cn.
- Publication Type:Journal Article
- Keywords:
acute myeloid leukemia;
gene mutation
- MeSH:
Humans;
Genomics;
Leukemia, Myeloid, Acute/genetics*;
Myosin Heavy Chains
- From:
Journal of Experimental Hematology
2022;30(6):1661-1667
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE:To explore mutational characteristics of acute myeloid leukemia (AML) patients with CBFβ-MYH11+ and analyze the correlation between the mutations and partial clinical characteristics.
METHODS:A total of 62 AML patients with CBFβ-MYH11+ were included and 51 candidate genes were screened for their mutations using targeted next-generation sequencing (NGS). The exon 12 of NPM1 , FLT3-ITD , and TAD, bZIP domains of CEBPA were detected by genomic DNA-PCR combined with sanger sequencing.
RESULTS:Compared with RUNX1-RUNX1T1 + group, the patients with CBFβ-MYH11+ showed higher age, peripheral WBC level, initial induced complete remission (CR) rate, more commonly carried chromosomal abnormalities such as +22, and lower deletion ratio of sex chromosome (-X or -Y) (P<0.05). In AML patients with CBFβ-MYH11+, the most common mutation was NRAS , followed by KIT, KRAS , and FLT3-TKD . Compared with RUNX1-RUNX1T1+ group, NRAS and FLT3-TKD were more frequently mutated in patients with CBFβ-MYH11+ (51.6% vs 18.7%, 17.7% vs 3.8%) (P<0.05).
CONCLUSION:The genomic landscape and clinical characteristics of AML patients with CBFβ-MYH11+ are different from patients with RUNX1-RUNX1T1 +.
